Výsledky vyhledávání

The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine as a novel, nonpeptide substance P antagonist

Autor: J A, Lowe, S E, Drozda, R M, Snider, K P, Longo, S H, Zorn, J, Morrone, E R, Jackson, S, McLean, D K, Bryce, J, Bordner

Publikováno v: Journal of Medicinal Chemistry. 35:2591-2600

We describe the structure-activity relationship development of a series of quinuclidines which culminated in the first potent, selective, nonpeptide substance P (SP) antagonist, (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)methyl]-1- azabicycl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6c93241d63e20be5becaf5862a27bd6
https://doi.org/10.1021/jm00092a009

Zobrazit plný text záznamu

The pharmacology of weight gain with antipsychotics

Autor: D E, Casey, S H, Zorn

Publikováno v: The Journal of clinical psychiatry. 62

In general, antipsychotic agents have diverse actions on a wide range of neurotransmitter systems. Data strongly suggest that a number of these systems may play a role in the regulation of body weight. In addition to having very distinct pharmacologi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::47a8ce45f36c6d81e887cf67d2ccc98a
https://pubmed.ncbi.nlm.nih.gov/11926725

Zobrazit plný text záznamu

Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog

Autor: A A, Fossa, M J, DePasquale, J, Morrone, S H, Zorn, D, Bryce, J A, Lowe, S, McLean

Publikováno v: The Journal of pharmacology and experimental therapeutics. 281(1)

Panicogenic effects in humans of the selective cholecystokinin (CCK(B)) receptor agonist, cholecystokinin tetrapeptide (CCK4), have been reported to correlate with increases in heart rate (HR) and mean arterial pressure (MAP). Previous investigators

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5d68cd6e46827f3b6166693cc58d86ca
https://pubmed.ncbi.nlm.nih.gov/9103496

Zobrazit plný text záznamu

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

Autor: T F, Seeger, P A, Seymour, A W, Schmidt, S H, Zorn, D W, Schulz, L A, Lebel, S, McLean, V, Guanowsky, H R, Howard, J A, Lowe

Publikováno v: The Journal of pharmacology and experimental therapeutics. 275(1)

Ziprasidone (CP-88,059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects in preclinical assays predictive of antipsychotic activity. Whereas the compound is a dopamine antagonist in vitro and in vivo, its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7f0136d69e8f80db8e60dd3baa418c0e
https://pubmed.ncbi.nlm.nih.gov/7562537

Zobrazit plný text záznamu

(R)-nipecotic acid ethyl ester: a direct-acting cholinergic agonist that displays greater efficacy at M2 than at M1 muscarinic receptors

Autor: S H, Zorn, R S, Duman, A, Giachetti, R, Micheletti, E, Giraldo, P, Krogsgaard-Larsen, S J, Enna

Publikováno v: The Journal of pharmacology and experimental therapeutics. 242(1)

Previous reports have suggested that the ethyl ester of (R)-nipecotic acid ethyl ester [(R)-NAEE] displays cholinomimetic properties in vivo. The present study was undertaken to characterize more fully this action by examining the effects of (R)-NAEE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::07b799f102272e667c1f04649e5ab316
https://pubmed.ncbi.nlm.nih.gov/2886636

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání